Mass Spectrometry-Based Omics Strategies for Biomarker Discovery in Alzheimer’s Disease

Mass Spectrometry-based Omics Strategies for Biomarker Discovery in Alzheimer’s Disease Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking. To address this challenge and uncover the diverse molecular signatures associated with AD progression, researchers are developing mass spectrometry (MS)-based omics strategies to obtain a chemical atlas in biofluids collected from AD patients and tissue samples. Dr. Lingjun Li from the University of Wisconsin-Madison will introduce multiplexed chemical tagging strategies to discover, identify and evaluate candidate biomarkers of AD in CSFs to elucidate disease progression and create a detailed biomolecular atlas of the brain of AD. Attend this webinar to: • Learn how to use systems biology omics strategies to probe protein and peptide dynamic changes in AD • Learn the design and application of chemical tagging approach for multiplex quantitation • Learn the basic workflow of spatial omics approach enabled by MALDI mass spectrometry imaging Lingjun Li Professor of Pharmaceutical Sciences and Chemistry School of Pharmacy and Department of Chemistry University of Wisconsin-Madison